New Data Suggests Glucosamine May Accelerate Dementia in Early Cognitive Decline

Key points

• Glucosamine use is linked to a 25% higher likelihood of mild cognitive impairment progressing to dementia.
• The supplement is associated with a 25% higher mortality risk within five years for those already diagnosed with dementia.
• Lab tests show that blocking the enzyme that makes glucosamine improves dementia symptoms in mice, while feeding them glucosamine worsens memory loss.
• Researchers emphasize that observational data cannot prove causality and that randomized controlled trials are required to confirm these findings.

Background

This story builds on earlier coverage from late September 2026, which first reported the University of Florida study linking glucosamine to faster Alzheimer's progression. The new findings provide additional details on the biological mechanisms, specifically the role of glycan structures, and include animal model data that supports the observational human data.

How outlets are covering it

Prevention and ScienceAlert both report on the same study but emphasize different aspects. Prevention focuses on the headline finding of the 25% higher risk, while ScienceAlert provides a more detailed breakdown of the biological mechanism, including the role of glycans and the mouse experiments. ScienceAlert also highlights the contrast between the findings in cognitively healthy adults versus those with early memory loss, a nuance less prominent in the Prevention summary. Both outlets agree on the need for further research to establish causality.

Why it matters

Glucosamine is taken by over 40 million Americans, making it a widely used supplement. If the findings hold up, it could have significant implications for the millions of older adults who use it for joint health, particularly those with early cognitive issues. The study also highlights the potential for new drug targets, as the abnormal sugar-tagging in the brain may be a novel hallmark of Alzheimer's disease.

What to watch

Researchers plan to follow dementia patients who discontinued glucosamine to see if their disease progression differs from those who continue taking it. This will help determine if the supplement is a causal factor or merely associated with the progression of dementia. Further randomized controlled trials are needed to confirm the findings and establish a clear cause-and-effect relationship.